BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 29620166)

  • 21. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
    Zhu L; Lopez S; Bellone S; Black J; Cocco E; Zigras T; Predolini F; Bonazzoli E; Bussi B; Stuhmer Z; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Tumour Biol; 2015 Jul; 36(7):5505-13. PubMed ID: 25669172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy.
    Pang M; Ma L; Gong R; Tolbert E; Mao H; Ponnusamy M; Chin YE; Yan H; Dworkin LD; Zhuang S
    Kidney Int; 2010 Aug; 78(3):257-68. PubMed ID: 20520592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apigenin induces caspase-dependent apoptosis by inhibiting signal transducer and activator of transcription 3 signaling in HER2-overexpressing SKBR3 breast cancer cells.
    Seo HS; Ku JM; Choi HS; Woo JK; Jang BH; Go H; Shin YC; Ko SG
    Mol Med Rep; 2015 Aug; 12(2):2977-84. PubMed ID: 25936427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
    Haura EB; Zheng Z; Song L; Cantor A; Bepler G
    Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation.
    Kumar G; Goldberg SN; Gourevitch S; Levchenko T; Torchilin V; Galun E; Ahmed M
    Radiology; 2018 Feb; 286(2):524-536. PubMed ID: 28880787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Icariside II induces apoptosis via inhibition of the EGFR pathways in A431 human epidermoid carcinoma cells.
    Wu J; Zuo F; Du J; Wong PF; Qin H; Xu J
    Mol Med Rep; 2013 Aug; 8(2):597-602. PubMed ID: 23807305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.
    Zahonero C; Aguilera P; Ramírez-Castillejo C; Pajares M; Bolós MV; Cantero D; Perez-Nuñez A; Hernández-Laín A; Sánchez-Gómez P; Sepúlveda JM
    Mol Cancer Ther; 2015 Jul; 14(7):1548-58. PubMed ID: 25939761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
    Festuccia C; Gravina GL; Millimaggi D; Muzi P; Speca S; Ricevuto E; Vicentini C; Bologna M
    Oncol Rep; 2007 Aug; 18(2):503-11. PubMed ID: 17611677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C-terminal tensin-like protein mediates invasion of human lung cancer cells and is regulated by signal transducer and activator of transcription 3.
    Bennett DT; Reece TB; Foley LS; Sjoberg A; Meng X; Fullerton DA; Weyant MJ
    J Thorac Cardiovasc Surg; 2015 Jan; 149(1):369-75. PubMed ID: 25439778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
    Wang WJ; Li CF; Chu YY; Wang YH; Hour TC; Yen CJ; Chang WC; Wang JM
    Clin Cancer Res; 2017 Jan; 23(2):503-513. PubMed ID: 27435393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quercetin induces caspase-dependent extrinsic apoptosis through inhibition of signal transducer and activator of transcription 3 signaling in HER2-overexpressing BT-474 breast cancer cells.
    Seo HS; Ku JM; Choi HS; Choi YK; Woo JK; Kim M; Kim I; Na CH; Hur H; Jang BH; Shin YC; Ko SG
    Oncol Rep; 2016 Jul; 36(1):31-42. PubMed ID: 27175602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
    Djerf EA; Trinks C; Abdiu A; Thunell LK; Hallbeck AL; Walz TM
    Melanoma Res; 2009 Jun; 19(3):156-66. PubMed ID: 19434003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of dacomitinib in patients with HER2-positive gastric cancer.
    Oh DY; Lee KW; Cho JY; Kang WK; Im SA; Kim JW; Bang YJ
    Gastric Cancer; 2016 Oct; 19(4):1095-1103. PubMed ID: 26581547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.